CHM

0.00%

1.4¢ chimeric therapeutics limited

Ann: 1st patient dosed in CHM 0201 Vactosertib trial, page-13

First 13 Last

Share
Profile

Follow
DrillDown2014

263 Posts.

64

11/01/24

08:23

Post #: 71823943
Share

Originally posted by pfeifer1982: ↑

Just noticed that the CHM 0201 Vactosertib trial is currently suspended (temporarily) due to insufficient staff (Christmas break?):

https://clinicaltrials.gov/study/NCT05400122?tab=table

Primary Completion Date however remains unchanged (Estimated): 1 June 2024.

Given the time Primary Outcome (1.) being 28 days after infusion, that would indicate dosing of the last patient to occur beginning of May (estimated).

Also worth noting that the trial seeks to enrol "up to 12 patients":
https://ascopubs.org/doi/abs/10.1200/JCO.2023.41.4_suppl.TPS273

https://chimerictherapeutics.com/our-pipeline/#our-pipeline

This trial is not the same as the ADVENT-AML Phase 1B trial:
https://clinicaltrials.gov/study/NCT05834244

https://chimerictherapeutics.com/our-pipeline/#our-pipeline

Both trials are utilising the non-engineered allogeneic CORE-NK platform (CHM 0201), which is different to the autologous therapy CHM 1101 (CLTX), which recently dosed the last patient in a Phase 1A dose escalation study:
https://clinicaltrials.gov/study/NCT04214392

https://www.businessnews.com.au/article/Chimeric-moves-US-brain-cancer-trial-to-next-stage

Positive Preliminary Data was announced in October last year:

https://chimerictherapeutics.com/wp-content/uploads/2023/10/ASX-Announcement-23Oct2023-2627696.pdf

CLTX is currently tested in a Phase 1B trial:
https://clinicaltrials.gov/study/NCT05627323

https://chimerictherapeutics.com/our-pipeline/#clinical-trials

CHM 2101, an autologous CDH17 CAR T-cell therapy is due to start recruitment within the next 6 months in a Phase 1 dose escalation study, with Phase 2 dosing based on results from Phase 1:
https://classic.clinicaltrials.gov/ct2/show/NCT06055439

So much to see here...

Expand

will be interested to learn just how many patients were recruited as recruitment as fist dose was nearly 11 months prior to recruitment suspension.

would preliminary data be expected to be announced around the primary completion date or is the timing totally independent of this date? Not sure how closely you follow these trials but you seem to stay updated.

thanks for posting the trial links

CHM Price at posting: 3.4¢ Sentiment: Buy Disclosure: Held
1 Upvote

0 Great analysis

Reply

Top Stories

COD

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

BCI

BCI reaches close of funding facility for salt-first part of Mardie project

WCN

White Cliff jumps 24% on 'bonanza grade' copper rock chips at Rae project, Canada

SLS

Solstice Minerals to ramp up drilling campaign at Yarri Gold Project

CKA

Cokal upgrades infrastructure for BBM ramp-up in Indonesia

Week 40 Wrap: China's nonsensical stimmy hype wanes (shocking!); HotCopper's picks; oil & inflation

NTI

Neurotech knocked back by FDA as agency declares target condition not rare enough for special status

BUX

Buxton projects new graphite province discovery at WA Narryer play

RCE

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

ACW

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

There are more pages in this discussion • 4 more messages in this thread...

First 13 Last

Add CHM (ASX) to my watchlist

(20min delay)
Last 1.4¢		Change 0.000(0.00%)		Mkt cap ! $12.67M

Open	High	Low	Value	Volume
0.0¢	0.0¢	0.0¢	$0	0

Ann: 1st patient dosed in CHM 0201 Vactosertib trial, page-13

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

BCI reaches close of funding facility for salt-first part of Mardie project

White Cliff jumps 24% on 'bonanza grade' copper rock chips at Rae project, Canada

Solstice Minerals to ramp up drilling campaign at Yarri Gold Project

Cokal upgrades infrastructure for BBM ramp-up in Indonesia

Week 40 Wrap: China's nonsensical stimmy hype wanes (shocking!); HotCopper's picks; oil & inflation

Neurotech knocked back by FDA as agency declares target condition not rare enough for special status

Buxton projects new graphite province discovery at WA Narryer play

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

Featured News

Featured News

Ann: 1st patient dosed in CHM 0201 Vactosertib trial, page-13

Top Stories

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

BCI reaches close of funding facility for salt-first part of Mardie project

White Cliff jumps 24% on 'bonanza grade' copper rock chips at Rae project, Canada

Solstice Minerals to ramp up drilling campaign at Yarri Gold Project

Cokal upgrades infrastructure for BBM ramp-up in Indonesia

Week 40 Wrap: China's nonsensical stimmy hype wanes (shocking!); HotCopper's picks; oil & inflation

Neurotech knocked back by FDA as agency declares target condition not rare enough for special status

Buxton projects new graphite province discovery at WA Narryer play

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

Featured News

Featured News